Holen Sie sich die Stockscreener-App
4.24
1.68%
0.07
Handel nachbörslich:
4.25
0.010
+0.24%
Schlusskurs vom Vortag:
$4.17
Offen:
$4.19
24-Stunden-Volumen:
17,374
Relative Volume:
0.10
Marktkapitalisierung:
$5.01M
Einnahmen:
$12.99M
Nettoeinkommen (Verlust:
$-27.45M
KGV:
-0.00238
EPS:
-1779.0561
Netto-Cashflow:
$-25.59M
1W Leistung:
+7.07%
1M Leistung:
-33.75%
6M Leistung:
-83.29%
1J Leistung:
-99.21%
1-Tages-Spanne:
$4.13
$4.25
1-Wochen-Bereich:
$3.97
$4.634
52-Wochen-Spanne:
$3.84
$583.20
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Firmenname
Aptevo Therapeutics Inc
Sektor
Branche
Telefon
206-838-0500
Adresse
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
4.24 | 4.93M | 12.99M | -27.45M | -25.59M | -1,779.06 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-11-05 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-10-05 | Fortgesetzt | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Aktie (APVO) Neueste Nachrichten
APVO Technical Analysis & Stock Price Forecast - Intellectia AI
APVO Forecast, Price Target & Analyst Ratings | APTEVO THERAPEUTICS INC (NASDAQ:APVO) - ChartMill
Update Recap: Can Aptevo Therapeutics Inc sustain its profitabilityMarket Movers & Risk Managed Investment Signals - baoquankhu1.vn
Institution Moves: Will IBEX outperform during market ralliesWeekly Risk Summary & Smart Allocation Stock Tips - baoquankhu1.vn
Nasdaq Moves: What are Aptevo Therapeutics Incs recent SEC filings showing2026 Buyback Activity & Expert Curated Trade Setups - baoquankhu1.vn
Risk Report: Is Aptevo Therapeutics Inc impacted by rising rates2026 Price Targets & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Aptevo’s Mipletamig Shows 86% Clinical Benefit Rate in Frontline AML Trial - citybuzz -
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment - NewMediaWire
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment | Corporate - EQS News
Aptevo Rises on AML Data—But Will It Hold? - Bitget
Aptevo Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
10-K - sec.gov
Aptevo Therapeutics 10-K: Net loss $25.97M, EPS $(87.27) - TradingView
Aptevo Therapeutics (NASDAQ: APVO) outlines bispecific cancer pipeline and AML data - Stock Titan
[8-K] Aptevo Therapeutics Inc. Reports Material Event - Stock Titan
APVO Achieves Significant Advances in Clinical Pipeline and Capi - GuruFocus
Aptevo Provides State of the Business Report and 2025 Financial Results - Bitget
Aptevo (APVO) Strengthens Financial Position for Future Operatio - gurufocus.com
No CRS in 28 AML patients as Aptevo adds 3 CD3 drug candidates - Stock Titan
APVO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Aptevo Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aptevo Therapeutics Inc.: Fundamental Analysis and Financial Ratings | AP81 | US03835L5049 - marketscreener.com
APVO Stock Price, Quote & Chart | APTEVO THERAPEUTICS INC (NASDAQ:APVO) - ChartMill
Aptevo Therapeutics Inc.: Fundamental Analysis and Financial Ratings | APVO | US03835L4059 - marketscreener.com
Aptevo to Participate in March 2026 Conferences - ACCESS Newswire
Aptevo sends incoming CEO to Roth, spotlights trispecific drugs in Lisbon - Stock Titan
Hedge Fund Moves: Whats next for Aptevo Therapeutics Inc stock2026 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn
Aptevo Therapeutics implements 1-for-18 reverse stock split - MSN
Pharma News: Is GeoVax Labs Inc Equity Warrants ROE strong enough2026 Stock Rankings & Weekly High Conviction Ideas - baoquankhu1.vn
Aptevo shares drop despite encouraging AML trial results - MSN
Aptevo’s Mipletamig Shows 86% Clinical Benefit Rate With No CRS in Frontline AML, Promising Safety and Efficacy Data 1 - Minichart
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Aptevo Reports Promising Interim Data for AML Therapy - TipRanks
Aptevo Therapeutics: Mipletamig Shows 86% Clinical Benefit Rate with No CRS in Frontline AML - TradingView
Aptevo Therapeutics Inc Announces New Interim Data For Mipletamig In Combination With Venetoclax And Azacitidine - marketscreener.com
Aptevo Therapeutics (APVO) reports 86% benefit, no CRS in mipletamig AML data - Stock Titan
Aptevo Therapeutics (APVO) Reveals Promising Results in AML Tria - GuruFocus
Aptevo Lists Lower on New Developments - Baystreet.ca
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Aptevo Therapeutics stock tumbles despite positive trial data - Investing.com India
Aptevo Therapeutics stock tumbles despite positive trial data By Investing.com - Investing.com UK
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50% - Bitget
Aptevo Therapeutics Stock Rallies On 100% Remission Rate In Acute Myeloid Leukemia Trial Cohort - MSN
Panic Selling: Is Aptevo Therapeutics Inc stock trending bullishQuarterly Investment Review & Daily Price Action Insights - baoquankhu1.vn
10 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
APVO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aptevo Therapeutics (NASDAQ:APVO) Upgraded at Wall Street Zen - Defense World
Finanzdaten der Aptevo Therapeutics Inc-Aktie (APVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):